Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome

Annals of Internal Medicine

Volumn 119, Issue 8, 1993, Pages 771-778

  Casey, Larry C ^a   Balk, Robert A ^a   Bone, Roger C ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVAL TIME;

EID: 0027731546     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-119-8-199310150-00001     Document Type: Article

References (44)

1. Centers for Disease Control. Increase in National Hospital Discharge Survey rates for septicemia - United States, 1979-1987. MMWR. 1990;39:31-4.
2. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med. 1987;317:653-8.
3. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med. 1987; 317:659-65.
4. Morrison DC, Ulevitch RJ. The effects of bacterial endotoxins on host mediation systems. Am J Pathol. 1978;93:526-617.
5. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med. 1991;324:429-436.
6. Greenman RL, Schein RM, Martin MA, Wenzel RP, Maclntyre NR, Emmanuel G, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA. 1991;266:1097-102.
7. Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987;316:379-85.
8. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest. 1988;81:1925-37.
9. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988;318:1481-6.
10. Tracey KJ, Beutler N, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-4.
11. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effect of endotoxin. Science. 1985;229:869-71.
12. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987;330:662-4.
13. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987;1:355-7.
14. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol. 1989;44:153-205.
15. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 1988;81:1162-72.
16. Cannon JG, Tompkins RG, Gelfand JA, Michie HR, Stanford GS, van der Meer JW, et al. Circulating imerleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis. 1990;161:79-84.
17. Luger A, Graf H, Schwartz HP, Stummvoll HK, Lager TA. Decreased serum interleukin 1 activity and monocyte interleukin 1 production in patients with fatal sepsis. Crit Care Med. 1986;14:458-61.
18. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J. 1991;5:338-43.
19. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med. 1989;169:333-8.
20. Hack CE, De Groot ER, Fell-Bersma RJ, Nuyens JH, Strack Van Schyndel RJ, Eerenberg-Belmer AJ, et al. Increased plasma levels of interleukin-6 in sepsis. Blood. 1989;74:1704-10.
21. Preiser JC, Schmartz D, Van der Linden P, Content J, Vanden Bussche P, Buurman W, et al. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog. Cytokine. 1991;3:1-4.
22. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA, et al. Sepsis syndrome: a valid clinical entity. Crit Care Med. 1989;17:389-93.
23. Roth RI, Levin FC, Levin J. Optimization of detection of bacterial endotoxin in plasma with the Limulus test. J Lab Clin Med. 1990; 116:153-61.
24. Davidson M, Tempest B, Palmer DL. Bacteriologic diagnosis of acute pneumonia. Comparison of sputum, transtracheal aspirates, and lung aspirates. JAMA. 1976;235:158-63.
25. Michie HR, Springs DR, Manogue KR, Sherman ML, Revhaug A, O'Dwyer ST, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 1988;104: 280-6.
26. Marano MA, Moldawer LL, Fong Y, Wei H, Minel J, Yurt R, et al. Cachectin/TNF production in experimental burns and Pseudomonas infection. Arch Surg. 1988;123:1383-8.
27. Ayala A, Wang P, Perrin MM, Ertel W, Chaudry IH. Differential alterations in plasma IL-6 and TNF levels after trauma and hemorrhage. Am J Physiol. 1991;260:R167-71.
28. Guice KS, Oldham KT, Caty MG, Johnson KJ, Ward PA. Neutrophil-dependent, oxygen-radical mediated lung injury associated with acute pancreatitis. Ann Surg. 1989;210:740-7.
29. Maury CP, Teppo AM. Raised serum levels of cachectin/tumor necrosis factor-alpha in renal allograft rejection. J Exp Med. 1987; 166:1132-7.
30. Abramowicz D, Schandene L, Goldman M, Crusiaux A, Vereerstraeten P, De Pauw L, et al. Release of tumor necrosis factor, interleukin-2 and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation. 1989; 47:606-8.
31. Maury CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum. 1989; 32:146-50.
32. Girardin E, Grau GE, Dayer JM, Roux-Lombard P, Lambert PH. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988;319:397-400.
33. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-41.
34. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol. 1985;135:3972-7.
35. Offner F, Philippe J, Vogelaers D, Colardyn F, Baele G, Baudrihaye M, et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med. 1990;116:100-5.
36. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont F. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med. 1989;17:975-8.
37. Okusawa S, Yancy KB, van ser Meer JW, Endres S, Lonnemann G, Hefter K, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1. J Exp Med. 1988;168:443-8.
38. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature. 1990;348:550-2.
39. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parrillo JE. Endotoxemia in human septic shock. Chest. 1991;99:169-75.
40. Deitch EA, Berg R, Specian R. Endotoxin promotes the translocation of bacteria from the gut. Arch Surg. 1987;122:185-90.
41. Natanson C, Danner RL, Ellin RJ, Hosseini JM, Peart KW, Banks SM, et al. The role of endotoxemia in cardiovascular dysfunction and mortality: Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest. 1989;83:243-51.
42. Rothstein JL, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci. 1988; 85:607-11.
43. White CW, Ghezzi P, Dinarello CA. Recombinant tumor necrosis factor/cachectin and interleukin 1 pretreatment decreases lung oxidized glutathione accumulation, lung injury, and mortality in rats exposed to hyperoxia. J Clin Invest. 1987;79:868-73.
44. Elias JA, Gustilo K, Baeder W, Freundlich B. Synergistic stimulation of fibroblast prostaglandin by recombinant interleukin 1 and tumor necrosis factor. J Immunol. 1987;138:3812-6.